Abstract
Relief of adverse events induced by chemotherapy is an important issue for patients, especially those with a poor prognosis, such as with pancreatic cancer. There are no reports of the relationship between gastroesophageal reflux disease (GERD) and chemotherapy, so we investigated the incidence of chemotherapy-induced GERD in patients undergoing treatment with gemcitabine or S-1 for pancreatic cancer and the effect of sodium rabeprazole (RPZ), a proton-pump inhibitor. GERD was diagnosed in 40% of the patients according to the Frequency Scale for Symptoms of GERD score, and RBZ therapy significantly improved their symptoms.
MeSH terms
-
2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use*
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Drug Combinations
-
Female
-
Gastroesophageal Reflux / chemically induced
-
Gastroesophageal Reflux / drug therapy*
-
Gemcitabine
-
Humans
-
Male
-
Middle Aged
-
Oxonic Acid / administration & dosage
-
Oxonic Acid / therapeutic use
-
Palliative Care / methods*
-
Pancreatic Neoplasms / drug therapy*
-
Prospective Studies
-
Proton Pump Inhibitors / therapeutic use*
-
Rabeprazole
-
Tegafur / administration & dosage
-
Tegafur / therapeutic use
Substances
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Drug Combinations
-
Proton Pump Inhibitors
-
Deoxycytidine
-
S 1 (combination)
-
Tegafur
-
Rabeprazole
-
Oxonic Acid
-
Gemcitabine